Multiple sclerosis vaccine - Connetics Corporation

Drug Profile

Multiple sclerosis vaccine - Connetics Corporation

Alternative Names: TCR multiple sclerosis vaccine

Latest Information Update: 01 Jun 1998

Price : $50

At a glance

  • Originator Connetics Corporation
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 01 Jun 1998 Discontinued-II for Multiple sclerosis in USA (Intradermal)
  • 04 Mar 1997 A study has been added to the Neurological Disorders immunogenicity section
  • 01 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top